Gary Owens, MD, Gary Owens Associates, says that trends in rheumatoid arthritis management are coming from the new 2012 American College of Rheumatology guidelines that call for earlier and more aggressive treatment of new patients as well as patients who are not doing well on existing therapies.
Gary Owens, MD, Gary Owens Associates, says that trends in rheumatoid arthritis management are coming from the new 2012 American College of Rheumatology guidelines that call for earlier and more aggressive treatment of new patients as well as patients who are not doing well on existing therapies. Dr Owens also discusses the drug costs associated with the treatment of rheumatoid arthritis. Health plans are looking to optimize value while managing cost.
This video was taken on November 8 at the NAMCP Fall Forum in Las Vegas, NV.
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More